Fujii Junichi, Shinke Go, Takeda Yutaka, Ohmura Yoshiaki, Katsura Yoshiteru, Kinoshita Mitsuru, Aoyama Shu, Kihara Yukari, Katsuyama Shinsuke, Ikeshima Ryo, Hiraki Masayuki, Sugimura Keijiro, Masuzawa Toru, Hata Taishi, Murata Kohei
Dept. of Surgery, Kansai Rosai Hospital.
Gan To Kagaku Ryoho. 2023 Jan;50(1):96-98.
We report a case of postoperative multiple recurrence of hepatocellular carcinoma(HCC)treated with atezolizumab plus bevacizumab. A 73-year-old man with a chief complaint of abdominal distention was indicated a 90-mm-sized tumor extending from the lateral hepatic segment to the extrahepatic region by a contrast-enhanced CT scan of the abdomen. He underwent a laparoscopic liver resection of the lateral segment for suspected HCC, and was diagnosed as pStage Ⅱ HCC. Six months after surgery, multiple recurrent at intrahepatic lesions and suspected lymph node recurrence or peritoneal dissemination were observed, and tumor markers were markedly elevated. The patient was diagnosed with multiple intrahepatic and extrahepatic recurrences of postoperative HCC and started combination chemotherapy with atezolizumab (1,200 mg/body)plus bevacizumab(15 mg/kg). After the initiation of the therapy, tumor size reduction and normalization of tumor markers were observed, and at 17 months postoperatively, tumor size reduction has been maintained and tumor markers were in the normal range. We report a case of postoperative intrahepatic and extrahepatic multiple recurrences of he patocellular carcinoma treated with atezolizumab plus bevacizumab.
我们报告了一例接受阿替利珠单抗联合贝伐单抗治疗的肝细胞癌（HCC）术后多次复发的病例。一名73岁男性，以腹胀为主诉，腹部增强CT扫描显示一个90毫米大小的肿瘤，从肝外侧段延伸至肝外区域。他因疑似HCC接受了肝外侧段的腹腔镜肝切除术，被诊断为pⅡ期HCC。术后6个月，观察到肝内病变多处复发，疑似淋巴结复发或腹膜播散，肿瘤标志物明显升高。该患者被诊断为术后HCC肝内和肝外多处复发，并开始接受阿替利珠单抗（1200mg/体）联合贝伐单抗（15mg/kg）的联合化疗。治疗开始后，观察到肿瘤大小缩小，肿瘤标志物恢复正常，术后17个月，肿瘤大小持续缩小，肿瘤标志物处于正常范围。我们报告了一例接受阿替利珠单抗联合贝伐单抗治疗的肝细胞癌术后肝内和肝外多处复发的病例。
